Hanna Rokita

Hanna Rokita

Auto-generated profile, based on publicly available information

Hanna Rokita

Laboratory of Molecular Genetics and Virology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Kraków, Poland

Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2014 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
MGMargaret Gil
Margaret Gil
MKMarcin P. Komorowski
Marcin P. Komorowski
MSMukund Seshadri
Mukund Seshadri
HRHanna Rokita
Hanna Rokita
AMA. J Robert McGray
A. J Robert McGray
DKDanuta Kozbor
Danuta Kozbor
Signals mediated by the chemokine CXCL12 and its receptor CXCR4 are involved in the progression of ovarian cancer through enhancement of tumor angiogenesis and immunosuppressive networks that regulate dissemination of peritoneal metastasis and development of cancer-initiating cells (CICs). In this study, we investigated the antitumor efficacy of a CXCR4 antagonist expressed by oncolytic vaccinia virus (OVV) against an invasive variant of the murine epithelial ovarian cancer cell line ID8-T. This variant harbors a high frequency of CICs that form multilayered spheroid cells and express the hyaluronan receptor CD44, as well as stem cell factor receptor CD117 (c-kit). Using an orthotopic ID8-T tumor model, we observed that i.p. delivery of a CXCR4 antagonist–expressing OVV led to reduced metastatic spread of tumors and improved overall survival compared with oncolysis alone. Inhibition of tumor growth with the armed virus was associated with efficient killing of CICs, reduced expression of ascitic CXCL12 and vascular endothelial growth factor, and decreases in i.p. numbers of endothelial and myeloid cells, as well as plasmacytoid dendritic cells. These changes, together with reduced recruitment of T regulatory cells, were associated with higher ratios of IFN-γ+/IL-10+ tumor-infiltrating T lymphocytes, as well as induction of spontaneous humoral and cellular antitumor responses. Similarly, the CXCR4 antagonist released from virally infected human CAOV2 ovarian carcinoma cells inhibited peritoneal dissemination of tumors in SCID mice, leading to improved tumor-free survival in a xenograft model. Our findings demonstrate that OVV armed with a CXCR4 antagonist represents a potent therapy for ovarian CICs with a broad antitumor repertoire.

1 February 2009 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
BPBarbara S. Paugh
Barbara S. Paugh
LBLauren Bryan
Lauren Bryan
SPSteven W. Paugh
Steven W. Paugh
KWKatarzyna M. Wilczynska
Katarzyna M. Wilczynska
SASilvina M. Alvarez
Silvina M. Alvarez
TKTomasz Kordula
Tomasz Kordula
Chronic inflammation and inflammatory cytokines have recently been implicated in the development and progression of various types of cancer. In the brain, neuroinflammatory cytokines affect the growth and differentiation of both normal and malignant glial cells, with interleukin 1 (IL-1) shown to be secreted by the majority of glioblastoma cells. Recently, elevated levels of sphingosine kinase 1 (SphK1), but not SphK2, were correlated with a shorter survival prognosis for patients with glioblastoma multiforme. SphK1 is a lipid kinase that produces the pro-growth, anti-apoptotic sphingosine 1-phosphate, which can induce invasion of glioblastoma cells. Here, we show that the expression of IL-1 correlates with the expression of SphK1 in glioblastoma cells, and neutralizing anti-IL-1 antibodies inhibit both the growth and invasion of glioblastoma cells. Furthermore, IL-1 up-regulates SphK1 mRNA levels, protein expression, and activity in both primary human astrocytes and various glioblastoma cell lines; however, it does not affect SphK2 expression. The IL-1-induced SphK1 up-regulation can be blocked by the inhibition of JNK, the overexpression of the dominant-negative c-Jun(TAM67), and the down-regulation of c-Jun expression by small interference RNA. Activation of SphK1 expression by IL-1 occurs on the level of transcription and is mediated via a novel AP-1 element located within the first intron of the sphk1 gene. In summary, our results suggest that SphK1 expression is transcriptionally regulated by IL-1 in glioblastoma cells, and this pathway may be important in regulating survival and invasiveness of glioblastoma cells.

12 September 2007 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
BPBarbara S. Paugh
Barbara S. Paugh
SPSteven W. Paugh
Steven W. Paugh
LBLauren Bryan
Lauren Bryan
DKDmitri Kapitonov
Dmitri Kapitonov
KWKatarzyna M. Wilczynska
Katarzyna M. Wilczynska
TKTomasz Kordula
Tomasz Kordula
Patients with gliomas expressing high levels of epidermal growth factor receptor (EGFR) and plasminogen activator inhibitor‐1 (PAI‐1) have a shorter overall survival prognosis. Moreover, EGF enhances PAI‐1 expression in glioma cells. Although multiple known signaling cascades are activated by EGF in glioma cells, we show for the first time that EGF enhances expression of PAI‐1 via sequential activation of c‐Src, protein kinase C delta (PKCδ), and sphingosine kinase 1 (SphK1), the enzyme that produces sphingosine‐1‐phosphate. EGF induced rapid phosphorylation of c‐Src and PKCδ and concomitant translocation of PKCδ as well as SphK1 to the plasma membrane. Down‐regulation of PKCδ abolished EGF‐induced SphK1 translocation and up‐regulation of PAI‐1 by EGF;whereas, down‐regulation of PKCα had no effect on the EGF‐induced PAI‐1 activation but enhanced its basal expression. Similarly, inhibition of c‐Src activity by PP2 blocked both EGF‐induced translocation of SphK1 and PKCδ to the plasma membrane and up‐regulation of PAI‐1 expression. Furthermore, SphK1 was indispensable for both EGF‐induced c‐Jun phosphorylation and PAI‐1 expression. Collectively, our results provide a functional link between three critical downstream targets of EGF, c‐Src, PKCδ, and SphK1 that have all been implicated in regulating motility and invasion of glioma cells.—Paugh, B. S., Paugh, S. W., Bryan, L., Kapitonov, D., Wilczynska, K. M., Gopalan, S. M., Rokita, H., Milstien, S., Spiegel, S., and Kordula, T. EGF regulates plasminogen activator inhibitor‐1 by a pathway involving c‐Src, PKCδ, and sphingosine kinase 1 in glioblastoma cells. FASEB J. 22, 4557–465 (2008)

1 August 2009 in Cancer Letters
Verified
Journal Article
Closed access
AKAleksandra Kowalczyk
Aleksandra Kowalczyk
MGMałgorzata Gil
Małgorzata Gil
IHIrena Horwacik
Irena Horwacik
ŻOŻaneta Odrowąż
Żaneta Odrowąż
DKDanuta Kozbor
Danuta Kozbor
HRHanna Rokita
Hanna Rokita

6 February 2010 in BMC Molecular Biology
Verified
Journal Article
Open access
PDF file
AKAneta Kasza
Aneta Kasza
PWPaulina Wyrzykowska
Paulina Wyrzykowska
IHIrena Horwacik
Irena Horwacik
PTPiotr Tymoszuk
Piotr Tymoszuk
DMDanuta Mizgalska
Danuta Mizgalska
JJJolanta Jura
Jolanta Jura
MCPIP is a novel CCCH zinc finger protein described as an RNase engaged in the regulation of immune responses. The regulation of expression of the gene coding for MCPIP - ZC3H12A is poorly explored. Here we report that the proinflammatory cytokine IL-1β rapidly induces the synthesis of MCPIP in primary monocyte-derived macrophages and HepG2 cells. This up-regulation takes place through the MAP kinase pathway and following activation of the transcription factor Elk-1. Using a ZC3H12A reporter construct we have shown that a ZC3H12A promoter region, stretching from -76 to +60, mediates activation by IL-1β. This region contains binding sites for Elk-1 and its partner SRF. Chromatin immunoprecipitation analysis confirms in vivo binding of both transcription factors to this region of the ZC3H12A promoter. We conclude that the transcription factor Elk-1 plays an important role in the activation of ZC3H12A expression in response to IL-1β stimulation.

18 November 2011 in Cell Biochemistry and Function
Verified
Journal Article
Closed access
PDF file
Malgorzata IciekMalgorzata Iciek
Malgorzata Iciek
IKInga Kwiecien
Inga Kwiecien
GCGrażyna Chwatko
Grażyna Chwatko
MSMaria Sokołowska‐Jeżewicz
Maria Sokołowska‐Jeżewicz
DKDanuta Kowalczyk‐Pachel
Danuta Kowalczyk‐Pachel
HRHanna Rokita
Hanna Rokita